Brief: Compugen Presents New Research Data Further Supporting PVRIG As A Potentially Promising Target For Cancer Immunotherapy
27/10/2020 11:42
Oct 27 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN PRESENTS NEW RESEARCH DATA FURTHER SUPPORTING
PVRIG AS
A POTENTIALLY PROMISING TARGET FOR CANCER IMMUNOTHERAPY
Source text for Eikon: ID:nPn8yDWWpa
Further company coverage: CGEN.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025